Drugs / ferric hydrochloride polymaltose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01676740 | Nov 2012 → Dec 2013 | — | Meir Medical Center | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ferric hydrochloride polymaltose | “Hematinic therapy will consist of oral ferric hydrochloride polymaltose 200 mg/d and folic acid 0.4 mg/d; sublingual vitamin B12 1000 µg three times a week” NCT01676740 ↗ |
| Route | Oral | “oral ferric hydrochloride polymaltose 200 mg/d” NCT01676740 ↗ |